Roche (ROG:CH) has been leading the charge on Covid-19 testing since the early days of the pandemic. Indeed, the Swiss healthcare giant has launched a number of specialist kits to detect the virus – from tests that reveal whether a patient is currently infected, to antibody tests that show whether someone has been infected. At the same time, the group is also working to fight the symptoms of the disease – it is currently monitoring the effectiveness of six different medicines across 28 clinical trials.
Tackling Covid-19 pandemic
Diversified revenue streams
Hit by coronavirus disruption
Withholding tax complications
These efforts to tackle Covid-19 are testament to Roche’s leadership in the complementary fields of diagnostics and pharmaceuticals. Its bosses say that its in-house expertise in both domains puts it at the forefront of personalised care – working to “fit the right treatment to each patient in the best way possible”.